Fluoxetine (hydrochloride)
Fluoxetine hydrochloride (LY 110140) is an antidepressant and a selective serotonin reuptake inhibitor.
Product Specifications
CAS Number
[56296-78-7]
Product Name Alternative
LY 110140
UNSPSC
12352005
Hazard Statement
H302, H318, H400
Target
Autophagy; Serotonin Transporter
Type
Reference compound
Related Pathways
Autophagy; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Neurological Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/fluoxetine-hydrochloride.html
Purity
99.97
Solubility
DMSO : ≥ 25 mg/mL|H2O : 8.33 mg/mL (ultrasonic)
Smiles
FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F.Cl
Molecular Formula
C17H19ClF3NO
Molecular Weight
345.79
Precautions
H302, H318, H400
References & Citations
[1]Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28 (9) :1562-71|[2]Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56 (8) :570-80.|[3]Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28 (6) :1374-84.|[4]Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) . 2002 Apr;160 (4) :353-61|[5]Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23 (3) :250-62.|[6]Su WJ, et al. Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance. J Neuroinflammation. 2017 Oct 30;14 (1) :210.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Fundam Clin Pharmacol. 2018 Aug;32 (4) :363-377.|Gut Pathog. 2025 Aug 21;17 (1) :65.|Int Immunopharmacol. 2025 May 10:158:114821.|J Neuroinflammation. 2017 Oct 30;14 (1) :210.|J Neuroinflammation. 2023 May 10;20 (1) :112.|Neuropharmacology. 2021 Feb 15;184:108410.|Neurotox Res. 2020 Dec;38 (4) :887-899.|Preprints. 2023 Dec 27.|World J Biol Psychiatry. 2024 Nov 29:1-18.|Adv Sci (Weinh) . 2025 Jun 10:e01981.|Behav Brain Res. 2017 Jan 15:317:62-70.|Behav Pharmacol. 2021 Feb 1;32 (1) :62-72.|Behav Pharmacol. 2024 Jun 1;35 (4) :227-238.|Behav Pharmacol. 2025 Apr 1;36 (2-3) :127-136.|Biochem Biophys Res Commun. 2020 Feb 19;522 (4) :862-868.|Biochem Pharmacol. 2023 Nov:217:115846.|Biomedicines. 2023 Apr 26;11 (5) :1279.|Brain Behav Immun. 2021 Jul:95:142-153.|Cell Prolif. 2021 Jan;54 (1) :e12953.|Cell Rep. 2021 Nov 2;37 (5) :109957.|Chem Biodivers. 2025 Sep 24:e00918.|Chemosphere. 2019 Jun:225:378-387.|Eur J Pharmacol. 2019 Jan 15:843:260-267.|Eur J Pharmacol. 2025 Dec 15:1009:178391.|J Clin Psychopharmacol. 2021 Sep-Oct;41 (5) :525-533.|J Psychiatr Res. 2023 Oct 19:168:91-99.|J Transl Med. 2024 Aug 22;22 (1) :785.|Nat Med. 2019 Sep;25 (9) :1428-1441.|Orebro University. 2024.|Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79 (Pt B) :258-267.|Reprod Toxicol. 2025 Jan 16:108840.|Research Square Preprint. 2023 Jun 16.|Research Square Preprint. 2023 Jun 29.|Research Square Preprint. 2024 Dec 16.|Virol J. 2024 Aug 8;21 (1) :181.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items